Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Saturday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

NYSE OGEN opened at $0.34 on Friday. The stock’s 50 day moving average is $0.64 and its 200 day moving average is $1.13. Oragenics has a twelve month low of $0.29 and a twelve month high of $7.74.

Oragenics (NYSE:OGEN) last announced its earnings results on Friday, August 9th. The company reported ($0.51) EPS for the quarter.

Institutional Trading of Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new position in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent quarter. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.